Overview
Prestige Q2 revenue of $274.1 mln beats analyst expectations despite a 3.4% decline yr/yr
Adjusted EPS of $1.07 for Q2 beats analyst estimates
Company repurchased 1.1 mln shares in Q2, enhancing shareholder value
Outlook
Prestige maintains fiscal 2026 revenue outlook at $1,100 mln to $1,115 mln
Company tightens fiscal 2026 adjusted EPS outlook to $4.54 to $4.58
Prestige expects fiscal 2026 free cash flow of $245 mln or more
Result Drivers
SUPPLY TIMING - Clear Eyes supply timing and retailer order timing helped surpass sales and earnings expectations
LIMITED SUPPLY - Revenue decline driven by limited ability to supply demand for Clear Eyes in Ear & Eye Care category
BRAND-BUILDING - Focus on brand-building and maintaining financial profile contributed to robust free cash flow
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$274.11 mln
$257.13 mln (7 Analysts)
Q2 Adjusted EPS
Beat
$1.07
$0.97 (7 Analysts)
Q2 Net Income
$42.21 mln
Q2 Gross Profit
$151.58 mln
Q2 Operating Expenses
$71.91 mln
Q2 Operating Income
$79.67 mln
Q2 Pretax Profit
$69.13 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Prestige Consumer Healthcare Inc is $80.00, about 25.2% above its November 5 closing price of $59.83
The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 15 three months ago
Press Release: ID:nGNX27sbzP
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)